Achillion Pharmaceuticals’ (ACHN) “Neutral” Rating Reiterated at Chardan Capital

Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN)‘s stock had its “neutral” rating restated by equities researchers at Chardan Capital in a report released on Sunday.

A number of other analysts have also issued reports on the company. Zacks Investment Research lowered Achillion Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, July 11th. BidaskClub lowered Achillion Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, July 25th. ValuEngine lowered Achillion Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Monday, September 11th. Ladenburg Thalmann Financial Services decreased their price objective on Achillion Pharmaceuticals from $9.00 to $6.50 and set a “buy” rating on the stock in a research note on Tuesday, September 12th. Finally, Robert W. Baird reiterated a “neutral” rating and set a $4.00 price objective (down from $5.00) on shares of Achillion Pharmaceuticals in a research note on Tuesday, September 12th. Two investment analysts have rated the stock with a sell rating, four have assigned a hold rating and four have given a buy rating to the company. Achillion Pharmaceuticals presently has an average rating of “Hold” and an average target price of $6.50.

Achillion Pharmaceuticals (NASDAQ ACHN) opened at 3.86 on Friday. The company’s market cap is $527.90 million. Achillion Pharmaceuticals has a 12 month low of $3.15 and a 12 month high of $9.19. The company has a 50 day moving average price of $4.48 and a 200-day moving average price of $4.20.

Achillion Pharmaceuticals (NASDAQ:ACHN) last released its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.16). During the same period in the prior year, the business earned ($0.14) EPS. Equities analysts predict that Achillion Pharmaceuticals will post ($0.66) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Achillion Pharmaceuticals’ (ACHN) “Neutral” Rating Reiterated at Chardan Capital” was reported by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this news story on another domain, it was copied illegally and republished in violation of U.S. & international copyright & trademark law. The original version of this news story can be read at https://sportsperspectives.com/2017/09/20/achillion-pharmaceuticals-achn-neutral-rating-reiterated-at-chardan-capital.html.

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Cambridge Investment Research Advisors Inc. increased its stake in Achillion Pharmaceuticals by 3.6% in the 2nd quarter. Cambridge Investment Research Advisors Inc. now owns 23,130 shares of the biopharmaceutical company’s stock worth $106,000 after acquiring an additional 800 shares during the last quarter. Canada Pension Plan Investment Board increased its stake in Achillion Pharmaceuticals by 4.7% in the 1st quarter. Canada Pension Plan Investment Board now owns 35,800 shares of the biopharmaceutical company’s stock worth $151,000 after acquiring an additional 1,600 shares during the last quarter. Schwab Charles Investment Management Inc. increased its stake in Achillion Pharmaceuticals by 0.6% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 457,341 shares of the biopharmaceutical company’s stock worth $2,100,000 after acquiring an additional 2,850 shares during the last quarter. Bank of Montreal Can increased its stake in Achillion Pharmaceuticals by 6.4% in the 2nd quarter. Bank of Montreal Can now owns 56,715 shares of the biopharmaceutical company’s stock worth $260,000 after acquiring an additional 3,410 shares during the last quarter. Finally, Wells Fargo & Company MN increased its stake in Achillion Pharmaceuticals by 1.8% in the 2nd quarter. Wells Fargo & Company MN now owns 219,647 shares of the biopharmaceutical company’s stock worth $1,009,000 after acquiring an additional 3,827 shares during the last quarter. Institutional investors and hedge funds own 74.11% of the company’s stock.

Achillion Pharmaceuticals Company Profile

Achillion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drug therapies for infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the alternative pathway of the complement system.

Analyst Recommendations for Achillion Pharmaceuticals (NASDAQ:ACHN)

Receive News & Ratings for Achillion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply